SCHRODINGER INC (SDGR) Stock News

Wondering what's happening in today's after-hours session?

The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today.

Mentions: PTN SLP WHLR ONVO ...

Schrödinger to Announce First Quarter 2025 Financial Results on May 7

3 Momentum Stocks That Could Soar Post-Market Volatility

Three unexpected companies have rallied quickly in the period following tariff-related market turbulence; can they maintain momentum?

Mentions: CERT NVS LOVE

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Schrödinger’s Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing

FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods.

Mentions: NVDA CRL DNA TEM ...

Schrödinger to Present Preclinical Data at AACR Annual Meeting

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

Schrödinger Reports Strong Fourth Quarter and Full-Year 2024 Financial Results

Earnings Scheduled For February 26, 2025

Mentions: CRH EYE MORN IONQ ...

Schrödinger to Participate in Upcoming Investor Conferences

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Schrödinger to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26

AI Pharma: 2 Paths to AI-Powered Drug Investment

AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.

Mentions: RXRX NVS LLY GPCR

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Schrödinger Provides Update on Progress Across the Business and Outlines 2025 Strategic Priorities

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Schrödinger to Present at Piper Sandler 36th Annual Healthcare Conference

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Schrödinger Broadens and Accelerates Predictive Toxicology Initiative

Schrödinger Reports Third Quarter 2024 Financial Results

Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis

Schrödinger to Present at Jefferies London Healthcare Conference

Schrödinger to Announce Third Quarter 2024 Financial Results on November 12

Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium